OSAKA, Japan & WALTHAM, Mass. — Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines, and Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP)...
Latest News
Barcelona, Spain – A group of scientists from various hospitals and research centers in Catalonia, led by Drs. Álvaro Carbayo and Ricard Rojas, researchers from the Neuromuscular Diseases Group at the Sant Pau Research Institute, in collaboration with Dr. Sergi Borrego-Écija and Dr. Ellen Gelpi from the Alzheimer’s Disease and...
Multi-inflammatory syndrome in children (MIS-C) was found to be a rare complication of SARS-CoV-2 infection, with a decreased occurrence of Kawasaki disease observed during the COVID-19 pandemic, according to study results published in Acta Paediatrica. In a nationwide, register-based study in Finland, researchers sought to explore the epidemiology of Kawasaki disease...
Vancouver, British Columbia — Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF), a Canadian biotechnology company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce the successful testing of a second-generation anti-cancer vaccine, called ARM-002TM, using its lead anti-cancer molecule AccuTOX®. When tested as a therapeutic vaccine in...
SINGAPORE – In a breakthrough study published in the highly respected journal Cancer Cell, researchers have decoded critical genetic factors in intestinal metaplasia patients, shedding light on early signs and prevention strategies for stomach cancer – often a “ticking time bomb” as patients experience no or only mild symptoms in...
NEW YORK — Delcath Systems, Inc. (NASDAQ: DCTH) , a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that the United States Food and Drug Administration (“FDA”) granted Delcath’s application for orphan-drug designation for the drug melphalan for the treatment...
QUEENSBURY, N.Y. – Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of results from a retrospective analysis conducted by researchers at the University of Tubingen, Germany. The study, titled “Characterization of...
When America Alcantara of Austin quit ducking behind her mother and burying her face in her pudgy hands, she gleefully snapped photographs of the adults she had met an hour earlier in a medical office and spun in every empty chair on Monday. The energetic 7-year-old will slow down for...
Los Angeles, CA – As Parkinson’s disease diagnoses continue to rise in the U.S., limited patient access to movement disorder specialists means the job of delivering the often-devastating, lifechanging news falls on primary care physicians or community neurologists who may not have the necessary expertise for this sensitive task. A...
TOKUSHIMA, Japan — As presented at 2022 ASCO Annual Meeting on June 6, 2022, DFP-14323 in combination with afatinib (20 mg/day) in stage III/IV non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutation positive in a Phase II clinical trial, has demonstrated fascinating longer median progression-free survival...